\begin{tabular*}{\textwidth}{@{\extracolsep\fill}clllllllllll@{\extracolsep\fill}}
\toprule
&  & \multicolumn{3}{c}{Final Selection (\%)$^1$} & \multicolumn{3}{c}{Allocations (\%)} & &  &  &  \\
\multirow{2}{2em}{Alpha} & \multirow{2}{2em}{Method} & \multirow{2}{2em}{MTD} & \multirow{2}{2em}{Above MTD} & \multirow{2}{2em}{Below MTD} & \multirow{2}{2em}{MTD} & \multirow{2}{2em}{Above MTD} & \multirow{2}{2em}{Below MTD} & \multirow{2}{2em}{Toxic~\%$^2$} & \multirow{2}{2em}{DLTs} & \multirow{2}{2em}{Trial Size} & \multirow{2}{2em}{Days}  \\ \\ 
\midrule
\multirow{4}{2em}{0} & CRM & 51 & 23 & 26 & 31 & 29 & 40 & 29 & 7.6 & 27.8 & 775\\
 & AIDE-CRM & 51 & 22 & 27 & 31 & 29 & 40 & 29 & 7.6 & 23.6 & 652\\
 & $\alpha$-CRM & 51 & 27 & 22 & 31 & 32 & 37 & 32 & 7.9 & 23.5 & 653\\
 & IPDE-POCRM & 52 & 29 & 20 & 31 & 33 & 36 & 33 & 8.0 & 23.1 & 640\\
\midrule
\multirow{4}{2em}{0.3} & CRM & 50 & 23 & 27 & 31 & 29 & 40 & 29 & 7.6 & 27.8 & 773\\
 & AIDE-CRM & 50 & 19 & 32 & 30 & 27 & 43 & 32 & 7.8 & 23.6 & 656\\
 & $\alpha$-CRM & 51 & 24 & 25 & 31 & 30 & 39 & 35 & 8.0 & 23.4 & 650\\
 & IPDE-POCRM & 52 & 25 & 23 & 31 & 31 & 37 & 37 & 8.2 & 23.1 & 638\\
\midrule
\multirow{4}{2em}{0.6} & CRM & 50 & 23 & 27 & 31 & 29 & 40 & 29 & 7.6 & 27.8 & 774\\
 & AIDE-CRM & 47 & 16 & 37 & 30 & 25 & 45 & 32 & 7.8 & 23.5 & 653\\
 & $\alpha$-CRM & 50 & 22 & 28 & 31 & 28 & 41 & 35 & 8.2 & 23.5 & 651\\
 & IPDE-POCRM & 51 & 22 & 27 & 31 & 30 & 39 & 36 & 8.4 & 23.0 & 637\\
\midrule
\multirow{4}{2em}{0.9} & CRM & 51 & 23 & 27 & 31 & 29 & 40 & 29 & 7.6 & 27.8 & 775\\
 & AIDE-CRM & 45 & 14 & 42 & 29 & 24 & 48 & 32 & 8.0 & 23.6 & 656\\
 & $\alpha$-CRM & 49 & 18 & 32 & 31 & 26 & 43 & 35 & 8.4 & 23.5 & 650\\
 & IPDE-POCRM & 51 & 18 & 31 & 31 & 27 & 42 & 37 & 8.6 & 22.9 & 636\\
\bottomrule
\end{tabular*}
